Professor of Surgery & Consultant Surgeon,
University of Tubingen
Director of PIPAC Program,
Professor Marc A. Reymond (MD)
Prof. Marc Reymond, born 1959, graduated as a physician from the University of Geneva, Switzerland. He was awarded with 3 years funding for academic fellowships and gained international experience at the Catholic University of Louvain (Belgium) and at the Erlangen University (Germany). In 1998 he became Associate Professor of surgery at the University of Geneva.
Prof. Marc Reymond is a certified gastrointestinal surgeon. In 1999, he became Head of Colorectal Surgery and Vice-Chairman of the Department of Surgery at the University of Magdeburg, Germany. From 2005-2011, he was Chairman and Head of the Department of Surgery at the Evangelic Hospital Bielefeld, a teaching hospital with 1500+ beds. From April 2012 to June 2016, he was Deputy Chairman and Head of Surgical Oncology at the Ruhr-University Bochum, where he developed Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). In July 2016, he moved to the University of Tübingen as the Director of the experimental and clinical PIPAC program.
From 1995 to 1999, Prof. Marc Reymond was research group leader in surgical oncology at the Foundation for Medical Research at the University of Geneva, Switzerland. He has published over 120 peer-reviewed original papers, invited and commissioned reviews. He is the Editor-in-Chief of “Pleura and Peritoneum” and an expert and/or a board member for 30+ national and international agencies, surgical training centers, committees and journals. Prof. Marc Reymond was an advisor to the French Prime Minister and Research Minister.
Prof. Marc Reymond is the Professor of Surgery at the University of Magdeburg and at the University of Tübingen, Germany. He was a state expert for medical license examinations in Switzerland and now in Germany. He has been invited as a teacher for numerous national and international postgraduate courses worldwide, including several named lectures. He published an evidence-based surgical textbook and re-edited a tradition-rich German surgical atlas.
In 2002, Prof. Marc Reymond completed a MBA in Science & Technology with LaSalle University, Philadelphia, USA. He is the founder of two biotech companies, of a non-profit biobank and holder of six innovation prizes. He is inventor or co-inventor of several patents and patent applications.
Prof. Marc Reymond is married and the father of 5 children. He likes skiing, climbing, sailing, gardening, Swiss cheese and good wine.
Prof. Florian Lordick is a Professor of Oncology at the University Hospital Leipzig, Germany. Prof. Florian Lordick was born in Munich in 1966, and carried out his medical training at the universities of Regensburg, Munich and Lausanne. He obtained his board certifications in internal medicine and in hematology and medical oncology and in 2002 he was nominated consultant physician at the Technical University of Munich. In July 2007 he was nominated assistant professor and became the head of the outpatient department at the National Centre for Tumour Diseases, University of Heidelberg. In 2009 he became head of hematology and oncology at the Klinikum Braunschweig and was nominated associate professor at the Hannover Medical School. Since 2012 he has been a full professor at the University of Leipzig and director of the comprehensive cancer center in the Leipzig University Hospital. In 2018 he was additionally appointed as director of the department of hematology and medical oncology at the University Hospital Leipzig, Germany.
Prof. Florian Lordick is a member of the board of directors and secretary of the “German Cancer Society” (DKG). He is a coordinator of the ESMO GI faculty and chairman of the EORTC GI Tract Cancer Working Group (2018-2020). He is the president of the International Gastric Cancer Congress (IGCC) to be held in Prague in May 2019. In 2019-2020 he will be a member of the ESMO / ASCO Global Curriculum Working Group.
Prof. Florian Lordick’s scientific focus is the clinical and translational research in gastrointestinal cancer, new drug development, molecular imaging, and response prediction. Dr. Lordick has authored and co-authored more than 280 peer-reviewed articles. He is co-editor and member of the editorial board of important international oncology journals including Annals of Oncology, the official journal of ESMO, and Gastric Cancer, the official journal of IGCA and a reviewer of multiple international and national research and funding societies.
University Cancer Center Leipzig,
Professor Florian Lordick (MD, PhD)
Professor Hyung-Ho Kim (MD, PhD)
Professor of Department of Surgery,
Seoul University College of Medicine
Director of Comprehensive Cancer Centre,
Seoul National University Bundung Hospital,
Prof. Kim Hyung-Ho was born in 1962 in Busan, South Korea. He graduated from Pusan National University College of Medicine in 1986. He was trained at department of surgery of Dong-A University Hospital in Busan for his residency and fellowship program between 1989 and 1996. He received Ph.D. from Dong-A University during his fellowship period. From 1998 to Feb. 2003 he worked for Dong-A University Hospital and Dong-A University College of Medicine as full time faculty.
In 2003 he moved to department of surgery, Seoul National University Bundang Hospital as founding members. Since 2009 he has served as a professor at department of surgery, Seoul National University College of Medicine. He was the chairman of department of surgery, Seoul National University Bundang Hospital between 2012 and 2016. Now, he is president of Comprehensive Cancer Center in Seoul National University Bundang Hospital.
He is a pioneer in minimally invasive surgery of gastric cancer treatment in Korea. He started to perform laparoscopic gastrectomy from 1996 and achieved 500 laparoscopic gastrectomy in 2006 which was the first in the world. His unit is one of biggest minimally invasive gastric cancer surgery center in the world. His team reported 3000 cases laparoscopic gastrectomy in 2014 with lower morbidity and higher survival rate than those of historical reports. The cumulative number of laparoscopic gastrectomy of his team currently has reached to 5000 cases. His team performed many onsite and tele-live surgery of laparoscopic gastrectomy for international and regional scientific meeting.
He is one of the foundation members of Korean Laparoscopic Gastrointestinal Surgery Study Group (KLASS) which was established from 2004. He was the president of KLASS from 2012 to 2015 and principal investigator of KLASS 01 trial to compare laparoscopic gastrectomy with open gastrectomy in phase III setting. He has been working in the editorial board on World Journal of Gastrointestinal surgery, Journal of Chinese Clinical Medicine, World Journal of Gastroenterology and taking a role as a director in many Korean professional societies.
He has been conducting many clinical trial to evaluate the role of MIS for gastric cancer which included sentinel navigation surgery, image guided surgery, and function preserving proximal gastrectomy with double tract reconstruction and making progress in various translation research as well. He published 123 SCI papers and 55 domestic papers. He is recognized as a world’s leading authority in MIS for gastric cancer.
Dr Martin Hϋbner, MD
Consultant Surgeon Oncologist,
Department of Visceral Surgery
Lausanne University Hospital CHUV
Dr. Martin Hübner is a full-time clinician who currently works as consultant for colorectal surgery at Lausanne University Hospital (CHUV), Switzerland. He is in charge of the treatment of Peritoneal Surface Malignancies offering HIPEC and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with one of the largest experiences with this new approach.
Born 1975 in Böblingen (Germany), Martin Hübner attended Medical School in Freiburg and Hamburg (German state examination 2002, doctoral level in electrophysiology). He pursued surgical training in Switzerland (surgical boards 2008) and performed sub-specialty training in colorectal surgery at Mayo Clinic, Rochester MN. He passed European (EBSQ coloprocotology) and Swiss Specialty boards (FMH Visceral Surgery) in 2012 and 2013, respectively.
Dr. Martin Hübner leads an active clinical research program on enhanced recovery after surgery (ERAS) and perioperative nutrition in particular (100+ scientific articles and PI of 6 RCTs). As scientific expert, he co-authored several recent evidence-based guidelines for ERAS and perioperative nutrition (ESPEN) and works as editor for Gastroenterology R&P, World J Surg, and World J Gastroenterol.
Dr. Wiebke Solaß (MD)
Institute of Pathology
University of Tuebingen
Dr. Wiebke Solass graduated as a physician from the University of Magdeburg, Germany in 2011 and received her Doctorate from this university in 2012 with the grade “magna cum laude”. She is currently Chief resident at the Institute of Pathology, University of Tuebingen, one of the elite universities in Germany.
In 2015, she was selected for the Ina Pilchmayr mentoring program for female junior academics, and in 2018 for the junior Academy of the German Society of Pathology. Dr. Solass’ research is focusing on gastrointestinal pathology, especially on genetics and molecular pathology, with a special interest for peritoneal metastasis. She published 42 peer-reviewed original papers, commissioned reviews, case reports and book chapters with 451 citations. She is the co-editor of the book “Pressurized IntraPeritoneal Chemotherapy: cancer under pressure” (De Gruyter publishers, Berlin Boston) and the Executive secretary of the peer-reviewed, open-access journal “Pleura and Peritoneum”. Dr. Solass has been invited to present her research at several national and international meetings in Germany and abroad.
Dr. Wiebke Solass is able to speak 3 languages, is a former athletics champion in Saxony-Anhalt and sailed to Antarctica. She is married and mother of two daughters.
Professor Marc Pocard (MD, PhD)
Department of Digestive & Oncologic Surgical,
International Society for the Study of Pleura & Peritoneum
Research Unit CAP Paris-Tech,
Professor Olivier Glehen (MD, PhD)
Head of General & Oncologic Surgery,
Centre Hospitalier Lyon Sud, and
Lyon Sud Charles Mérieux Medical Faculty
Prof. Olivier Glehen is at the Head of General and Oncologic Surgery Department in Centre Hospitalier Lyon Sud (Hospices Civils de Lyon) and in Lyon Sud Charles Mérieux Medical Faculty since 2012. He is the Director of the Peritoneal Carcinomatosis Research Group from the EMR 3738 (Lyon 1 University). He worked from 2002 to 2003 In Washington Cancer Institute as Research fellow with Paul Sugarbaker.
He organized the 6th and the 10th International Workshop on Peritoneal Surface Malignancy in Lyon on 2008 and in Paris in 2018.
His main research and clinical interests are the curative management of all peritoneal carcinomatosis (cytoreductive surgery, peritonectomy procedures and Hyperthermic Intraperitoneal Chemotherapy or HIPEC). He performs more than 200 combined procedures (cytoreductive surgery and HIPEC) per year. He also develops PIPAC procedures and intraperitoneal chemotherapy for neoadjuvant and palliative care.
He has published extensively in the area of peritoneal carcinomatosis (more than 250 articles indexed in Pubmed. He is at the Head of RENAPE (French Network on rare peritoneal disease) and BIG-RENAPE groups (National Clinic-Biological Database on Digestive Peritoneal Carcinomatosis).
He is the director of Inter-University Diploma on Peritoneal Carcinomatosis in France and is Reference Center for Tutorial Education for Peritoneal Surface Malignancies into European Society of Surgical Oncology
Dr. Olivia Sgarbura (MD, PhD)
Cancer Institute of Montpellier
Dr. Olivia Sgarbura is a surgical oncologist at the Montpellier Cancer Institute. Her clinical and research activity is focused on peritoneal and liver metastases, mainly of colorectal origin.
From the early times of her career, cancer surgery was her primary focus. As a medical student, she spent two summer practices at the Hospital of Bellvitge in Barcelona, in Prof. Joan Figueras’ HPB unit. The first part of her residency took place in a surgical oncology and HPB unit in Bucharest, Romania. Her PhD title was obtained in 2010 with a thesis on robotic-assisted surgical oncology, at a time when robotic surgery was only embraced by early adopters (2007-2010).
She did her fellowship at the Montpellier Cancer Institute, under the supervision of Dr. François Quénet, principal investigator of Prodige 7 trial. She completed her surgical education with the Inter-University Diploma of Peritoneal Carcinomatosis, leaded by Prof. Olivier Glehen and Prof. Marc Pocard and the European Diploma of Onco-Surgical Strategies in HPB, leaded by Prof. René Adam. She eventually became a practitioner at the Montpellier Cancer Institute and a researcher for SIRIC (Integrated Site of Research in Cancer).
In 2016 she started the NIPOX trial (phase I trial associating intraperitoneal oxaliplatin to systemic FOLFIRI for patients with unresectable peritoneal metastases of colorectal origin) and initiated the PIPAC program at the her institution. In early 2019, the MESOTIP trial (phase II clinical trial evaluating the role of PIPAC in alternance with systemic chemotherapy in the first line of treatment of unresectable peritoneal mesothelioma) received funding and approval from the French regulatory authorities. Olivia Sgarbura is part of the RENAPE and BIG-RENAPE groups (the French network for the treatment of peritoneal carcinomatosis).
Professor Rob Ramsay (MD, PhD)
Co-head GI Cancer Program
Group Leader - Differentiation and Transcription
Peter MacCallum Cancer Centre
305 Grattan Street, Melbourne
Prof. Rob Ramsay is the group leader of the Differentiation and Transcription Laboratory (since 1995) and Co-Head of the GI Cancer Program at Peter MacCallum Cancer Centre. His PhD in Biochemistry was gained at the University of Queensland based on research into melanoma genetics at the Queensland Institute for Medical Research.
He did post-doctoral training at Memorial Sloan Kettering Cancer Centre New York, NY and the Ludwig Institute, Melbourne and was a NHMRC Research Fellow - 1994-2016. His research interests span from cancer initiating cells in GI cancer to immunotherapy and cancer surgery. He is perhaps best known for his research on the oncoprotein, MYB and colon cancer. His research is now influencing the way cancer surgery is conducted and how immunotherapy might be applied to target metastatic lesions. His vision has coalesced into a focused research program at the laboratory/clinical interface within Peter Mac, a quaternary referral comprehensive cancer centre. Evidence has been built from the teams pre-clinical and clinical studies and applied in seven clinical trials/studies for which he leads the lab-based evaluations performing innovative research using patient-derived tumouroids and matching immune cells that address the tumour microenvironment in colorectal primary tumours and liver and peritoneal metastases.
To facilitate this research translational his team including 5 surgery fellows, research nurses and scientists has developed unique skills and paradigm shifting research platforms that have real-world clinical application and impact.
Professor Gary Lim (MD, PhD)
Professor of Respiratory Medicine,
University of Western Medicine
Consultant & Director of Pleural Services,
Respiratory Dept, Sir Charles Gairdner Hospital
Pleural Medicine Unit, Institute of Respiratory Health
NH & MRC / MRFF Practitioner Fellow
Prof. Gary Lee is a chest physician and professor with 18 years of experience in translational research of pleural diseases, especially pleural malignancies and infection. His pleural program includes a laboratory and a clinical research arm closely integrated with an active tertiary clinical pleural disease service which he directs. This research program is amongst the most active in the field. His work has translated to clinical practice on many occasions and contributed directly to reducing mortality, morbidity and healthcare costs in patient care.
He has published 240 original and invited papers (H-index 48; total citations >8000), and a grant record of over AUD $20 million. He has delivered 300+ invited lectures on pleural diseases, including at 100+ international conferences in 32 countries. He has served on many international pleural guideline panels and has a strong record in training clinical fellows and postdoctoral scientists.
Professor Wim Ceelen (MD, PhD)
Professor of Department of Surgery,
Director of Experimental Surgery Lab,
Senior Staff, GI Surgery,
Ghent University Hospital
Prof. Wim Ceelen graduated as a medical doctor in 1992 at Ghent University (Belgium) and later obtained his PhD at the same university with a doctoral thesis entitled 'Neoadjuvant multimodal therapy in rectal cancer'. Currently, he is a senior surgeon in the department of Gastrointestinal Surgery at the Ghent University Hospital and was appointed as Associate Professor in surgical oncology at Ghent University. He is a Senior Clinical Investigator with the FWO – Vlaanderen and is director of the Laboratory of Experimental Surgery at Ghent University.
Prof. Wim Ceelen has an interest in surgical oncology of the digestive tract and the peritoneum. His research includes functional and molecular imaging in animal tumor models and new approaches to intraperitoneal drug delivery. He is (co)author of over 180 PubMed cited publications and promoter of 7 completed and 4 ongoing PhD theses.
He has served as president of the Belgian Society of Surgical Oncology and board member of the European Society for Surgical Research. He is a member of the EORTC GI group, the Cochrane collaboration GI group, the Society of Surgical Oncology (SSO), ESSO, and the American College of Surgeons. Prof. Wim Ceelen is Editor-in -chief of Acta Chirurgica Belgica and associate editor of European Surgical Research, International Journal of Hyperthermia, Pleura and Peritoneum, and Frontiers in Surgical Oncology.
Asst. Prof. Lam Ka On (MD, PhD)
Department of Clinical Oncology,
LKS Faculty of Medicine,
The University of Hong Kong
Dr. Lam graduated from The University of Hong Kong with distinction in 2005. He was awarded the Frank Doyle Medal and the Rohan Williams Medal for his outstanding performance in the Fellowship examination of The Royal College of Radiologists.
He joined the Department of Clinical Oncology, LKS Faculty of Medicine, HKU as a clinical assistant professor in 2011. He was awarded the University of Hong Kong Overseas Fellowship in 2013 which funded his elective with Prof. David Cunningham and Dr. Ian Chau in the GI unit of the Royal Marsden, UK.
His research interests include NPC, gastroesophageal and colorectal cancer. He published in peer-review journals and has presented in various local and international cancer conferences. He has strong interest in novel treatment strategies for GI cancers and has led a phase I clinical trials in intraperitoneal chemotherapy for metastatic gastric cancer as well as being active in global immunotherapy studies. He is currently working on several government-funded projects on circulating tumor cells in different GI cancers.
Assoc. Prof. Maher Tabba (MD, MS, FACP, FCCP)
Associate Professor of Medicine & Surgery
Chief, Interventional Pulmonology & Thoracic Oncology Program
Department of Medicine
Division of Pulmonary & Critical Care Medicine & Sleep Disorders
Tufts University School of Medicine
United States of America
Positions: - Chief, Critical Care Medicine
Melrose-Wakefield Health Care System, Massachusetts, USA
- Faculty Governance of University College (Inaugural member)
Tufts University,Boston, Massachusetts
Medical Degree: Aleppo University ,Aleppo, Syria
Master in Science: Department of Human Genetics, Subfield: Gene Therapy
University of Michigan Medical School, Ann Arbor, Michigan, USA
Residency in Medicine: Department of Medicine, Wayne State University-Sinai Hospital Program
Detroit, Michigan, USA
Fellowship Pulmonary, Critical Care and Sleep Medicine
Division of Pulmonary & Critical Care and Environmental Medicine
Department of Medicine,
University of Missouri Health Science Center -Columbia School of Medicine, Columbia, Missouri, USA
Fellowship Interventional Pulmonology : Lahey Clinic Medical Center
Department of Pulmonary and Critical Care Medicine,
Tufts University School of Medicine, Burlington, Massachusetts
Postgraduate Diploma, Perioperative and Critical Care Echocardiography:
Department of Pharmacology, Faculty of Medicine
Royal Melbourne Hospital, University of Melbourne, Victoria, Australia
Founder and President, International Society of Pleural Diseases
President, New England States Chest Physicians
President, Northeastern Chapter, The American Society of Bronchology and Interventional Pulmonology
Director of Pulmonary and Critical Care fellowship Program at Tufts Medical Center for ten years.
Associate Curriculum Dean at University of Missouri-Columbia School of Medicine, Columbia, Missouri , USA for five years
Pleural diseases and airway diseases
Professor Michael Bau Mortensen (MD, PhD, DMSc)
Professor of Surgery,
Upper GI & HPB Section,
Department of Surgery
Odense Pancreas Center (OPAC),
Odense PIPAC Centre
Odense University Hospital,
Professor Michael Bau Mortensen, born 1962, graduated as a physician form Odense University in 1988. In 1996 he became certified specialist in General Surgery and defended his PhD on advanced ultrasound in upper GI tract cancer. In 2003 he became certified specialist in Gastrointestinal Surgery and was appointed Consultant Oncology Surgeon at Odense University Hospital. Three years later he became Associate Professor of Surgery and in 2012 nominated Clinical Professor at the University of Southern Denmark and Odense University Hospital. The same year he defended his dissertation (DMSc) – also concerning upper GI tract cancer patients.
Prof. Michael Bau Mortensen is the head of two multi-disciplinary centers (Odense Pancreas Center – Center of Clinical Excellence and Odense PIPAC Center) as well as Center for Surgical Ultrasound, Section for Advanced Endoscopy and the HPB & Upper GI Research Section, Odense University Hospital. Prof. Michael Bau Mortensen is former Chairman of the Danish Chapter of International Society of Surgery (ISS), Danish Pancreatic Cancer Group (DPCG) and Danish Pancreatic Cancer Database (DPCD) and present Chairman of the National Upper GI Tract Cancer Group (ØGC). Prof. Michael Bau Mortensen is also former Consultant Oncology Surgeon in the Second Opinion Section of the National Board of Health and present member of the Upper GI Tract Cancer Group under the National Board of Health.
Prof. Michael Bau Mortensen’s major research areas are upper GI and HPB cancer surgery, minimal invasive diagnosis, staging and treatment, advanced endoscopic and intraoperative ultrasound, PIPAC, and translational research. MBM has (co)authored 130+ peer review scientific articles, 6 books/book-chapters, and has sponsored 50+ clinical trials and 12 PhD studies. MBM has received 12 national/international awards, organized > 20 national/international congresses and raised > 3.5 million € for research.
Dr. Mohammad Alyami (MD)
Head of Department of Surgery and Surgical Oncology,
Head of Oncology Center,
Consultant of General, Colorectal, and Oncology Surgery,
King Khalid Hospital, Najran
Dr. Mohammad Alyami is a Consultant of General, Colorectal, and Oncology Surgery working at King Khalid Hospital, Najran, Saudi Arabia since 2018.
He is the head of department of Surgery and the Head of Oncology Center, at the same hospital. He is in charge of the treatment of Peritoneal Surface Malignancies offering CRS & HIPEC and PIPAC in addition to the colorectal and upper GI cancer surgery.
He was born in 1983 in Najran, Saudi Arabia, Graduated from the medical school in 2007. Then he moved to France where he had the French board of general and digestive surgery in 2014. He had three years fellowship in one of leading center in the management of peritoneal surface oncology (Lyon Sud university Hospital) and trained by his mentor by Prof. Glehen. He moved to Saudi Arabia in 2018 and started a new oncology center focused in peritoneal surface oncology (PIPAC, HIPEC).
His research interests include PIPAC, HIPEC, Colorectal Cancer. He has published more than 30 original and invited papers and he is a member in multiple international societies. He is one of the international ISSPP PIPAC trainer and he organized the 1st PIPAC training workshop in the middle-east in Dubai 2019.
Dr. Delia Cortes Guiral (MD, PhD)
European Certification on Peritoneal Surface Oncology
Delia Cortes-Guiral undertook her surgical training in Madrid and specialized in colo-rectal surgery (Fellow, 2 years, Madrid, Spain). She enrolled in the European School of Peritoneal Surface Oncology (ESSO; European Society of Surgical Oncology) After two years of exhaustive theoretical and specialized surgical training, she was first promotion and certified in Peritoneal Surface Surgical Oncology.
She has been responsible for the development of two programs of Peritoneal Surgical Oncology in Madrid, as part of a multidisciplinary team, not only offering cyto-reductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) but also PIPAC (pressurized intraperitoneal aerosolized chemotherapy). Applying her knowledge in laparoscopy she has been an active part in the development of the techniques of laparoscopic peritonectomy. She co-chaired and organized the first international course of laparoscopic management of peritoneal disease, a theoretical and hands-on course on minimally invasive treatment of peritoneal malignancies: laparoscopic peritonectomy with natural orifices extraction, laparoscopic HIPEC, PIPAC.Also veru active in the development of prehabilitation for patients undergoing CRS and HIPEC.
She is member of the Steering Committee of EYSAC-ESSO (European Young Surgeons and Alumni Club), SEOQ (Spanish Society of Surgical Oncology) and FESEO (Federation of Spanish Societies of Oncology)
She is also very actively involved in the development of social media as tools for surgical global education, she is responsible for #SoMe4Peritoneum @SPeritoneum in Twitter.
Prof. Marc Pocard did his residency in the Paris Hospitals and during the same time studied colorectal cancer biology at the Curie Institut. He worked during 5 years as a surgeon at the Gustave Roussy Institut in Paris during which he also had the opportunity to work on peritoneal metastatic diseases.
In 2006 he was nominated Professor in digestive surgery at the Paris Diderot University. He developed a peritoneal metastasis treatment program, in association with the French RENAPE network for rare peritoneal cancers.
In 2009 he created a research Unit at the INSERM on Angiogenesis and again in 2019 a research Unit specifically devoted to basic and translational research on peritoneal metastasis. He practices HIPEC and PIPAC in a routine manner and is involved in clinical trials related to peritoneal metastasis.
In 2018 he co-founded the ISSPP and was elected as the first president of the ISSPP society.